PC
MLTX icon

Periscope Capital’s MoonLake Immunotherapeutics MLTX Stock Holding History

Periscope Capital’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-50,000
Closed -$565K – 577
2020
Q4 		$565K Buy
+50,000
New +$531K 0.03% 293

Other funds holding MLTX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Periscope Capital's MLTX Position: Q1 2021 in Review

Periscope Capital sold out of MoonLake Immunotherapeutics (MLTX) in Q1 2021, closing a stake of 50,000 shares — an estimated $565K sold.

Periscope Capital first reported a position in MLTX in Q4 2020 and held it in 1 quarter. The position peaked at $565K in Q4 2020. 42 funds tracked by Wall St. Rank hold MLTX as of Q1 2021.

  • Periscope Capital reported no remaining MoonLake Immunotherapeutics position as of Q1 2021 after selling out during the quarter.
  • Periscope Capital sold 50,000 MoonLake Immunotherapeutics shares in Q1 2021, an estimated $565K.
  • Periscope Capital first reported a position in MoonLake Immunotherapeutics in Q4 2020 and held it in 1 quarter.
  • Periscope Capital's MoonLake Immunotherapeutics position peaked at $565K in Q4 2020.
  • 42 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2021.

Based on Periscope Capital's 13F filing for Q1 2021, filed 14 May 2021.